Abstract
US labelling for Rituxan [rituximab] has been updated to include a warning regarding hepatitis B reactivation and fulminant hepatitis,
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.2165/00128415-200410230-00001
Journal: Reactions Weekly | Publication Date: Oct 1, 2004 |
US labelling for Rituxan [rituximab] has been updated to include a warning regarding hepatitis B reactivation and fulminant hepatitis,
Join us for a 30 min session where you can share your feedback and ask us any queries you have